PDT Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

PDT Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-605	Closed	-$148K	–	884
2020 Q3	$148K	Buy	+605	New	+$188K	0.01%	661
2019 Q1	–	Sell	-427	Closed	-$130K	–	512
2018 Q4	$130K	Buy	427 +74	+21%	+$23.9K	0.01%	431
2018 Q3	$127K	Sell	353 -848	-71%	-$290K	0.01%	453
2018 Q2	$439K	Buy	1,201 +451	+60%	+$161K	0.02%	411
2018 Q1	$222K	Buy	+750	New	+$222K	0.01%	515
2015 Q2	–	Sell	-44	Closed	-$373K	–	1700
2015 Q1	$373K	Buy	+44	New	+$385K	0.01%	1108

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PDT Partners's EIGR Position: Q4 2020 in Review

PDT Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 605 shares — an estimated $148K sold.

PDT Partners first reported a position in EIGR in Q1 2015 and held it in 6 quarters. The position peaked at $439K in Q2 2018. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

PDT Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
PDT Partners sold 605 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $148K.
PDT Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
PDT Partners's Eiger BioPharmaceuticals, Inc. position peaked at $439K in Q2 2018.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.